Myron Czuczman

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. doi request reprint Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
    M S Czuczman
    Department of Medicine, Lymphoma Myeloma Section, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Ann Oncol 23:2356-62. 2012
  2. doi request reprint Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
    Myron S Czuczman
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Blood 119:3698-704. 2012
  3. doi request reprint Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY, USA
    Br J Haematol 157:438-45. 2012
  4. ncbi request reprint Combination chemotherapy and rituximab
    M S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Drugs 12:S15-9. 2001
  5. ncbi request reprint The first International Workshop on Non-Hodgkin's Lymphoma: taking a close look at current issues and future developments
    Myron Czuczman
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
    Leuk Lymphoma 44:S1-4. 2003
  6. doi request reprint Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
    Myron S Czuczman
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 14:1561-70. 2008
  7. ncbi request reprint Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 25:4285-92. 2007
  8. ncbi request reprint Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 48:97-103. 2007
  9. ncbi request reprint Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma
    Myron S Czuczman
    Roswell Park Cancer Institute, Elm and Carlton St, Buffalo, NY 14263 0001, USA
    J Clin Oncol 23:4390-8. 2005
  10. doi request reprint The future of CD20 monoclonal antibody therapy in B-cell malignancies
    Myron S Czuczman
    Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA
    Leuk Lymphoma 51:983-94. 2010

Detail Information

Publications66

  1. doi request reprint Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
    M S Czuczman
    Department of Medicine, Lymphoma Myeloma Section, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Ann Oncol 23:2356-62. 2012
    ..9 years. Notably, Follicular Lymphoma International Prognostic Index (FLIPI) correlated with ORR, CR rate, and PFS, and the low-risk FLIPI group (n = 12) achieved a 92% ORR, 75% CR/CRu rate, and 75% 3-year PFS...
  2. doi request reprint Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
    Myron S Czuczman
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Blood 119:3698-704. 2012
    ..The present study was registered at www.clinicaltrials.gov as NCT00394836...
  3. doi request reprint Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY, USA
    Br J Haematol 157:438-45. 2012
    ..No deaths have been reported. O-CHOP was safe and efficacious in patients with previously untreated FL, including high-risk FLIPI groups. This trial was registered at www.clinicaltrials.gov (NCT00494780)...
  4. ncbi request reprint Combination chemotherapy and rituximab
    M S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Drugs 12:S15-9. 2001
    ..A further study is underway to determine whether similar efficacy with less overall toxicity can be achieved using rituximab in combination with fludarabine...
  5. ncbi request reprint The first International Workshop on Non-Hodgkin's Lymphoma: taking a close look at current issues and future developments
    Myron Czuczman
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
    Leuk Lymphoma 44:S1-4. 2003
  6. doi request reprint Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
    Myron S Czuczman
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 14:1561-70. 2008
    ..Future research is geared to identify drugs and/or biological agents that are effective against RRCL...
  7. ncbi request reprint Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 25:4285-92. 2007
    ..To investigate the incidence of treatment-related myelodysplastic syndrome (t-MDS) and treatment-related acute myelogenous leukemia (t-AML) after treatment with ibritumomab tiuxetan radioimmunotherapy...
  8. ncbi request reprint Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 48:97-103. 2007
    ..Median event-free survival was 1.2 months and median overall survival was 3 months. Due to lack of efficacy and excessive toxicity, nelarabine is not recommended as monotherapy in adult patients with CTCL and STCL at this dose schedule...
  9. ncbi request reprint Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma
    Myron S Czuczman
    Roswell Park Cancer Institute, Elm and Carlton St, Buffalo, NY 14263 0001, USA
    J Clin Oncol 23:4390-8. 2005
    ..This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma...
  10. doi request reprint The future of CD20 monoclonal antibody therapy in B-cell malignancies
    Myron S Czuczman
    Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA
    Leuk Lymphoma 51:983-94. 2010
    ..New treatment strategies and novel anti-CD20 mAbs have the potential to enhance long-term outcomes for CLL and NHL...
  11. ncbi request reprint Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma
    M S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 23:694-704. 2005
    ..To evaluate the safety and efficacy of fludarabine plus rituximab in treatment-naive or relapsed patients with low-grade and/or follicular non-Hodgkin's lymphoma...
  12. doi request reprint Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas
    Myron Czuczman
    Lymphoma Myeloma Service, Department of Medicine Head, Lymphoma Translational Research Laboratory, Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 51:41-9. 2010
    ..This report summarizes the latest advances in our understanding of FL and HL, and demonstrates the different approaches required when developing novel treatment strategies for the two diseases...
  13. doi request reprint The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 154:477-81. 2011
    ..The most common grade 3/4 adverse events were reversible myelosuppression. Our results suggest that the original lymphoma histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy...
  14. ncbi request reprint Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma
    Francisco J Hernandez-Ilizaliturri
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Adv Hematol Oncol 2:606-18. 2004
    ..In this report we provide an overview of recent developments in target-specific therapies and review past, ongoing, and future research tiling this diverse group of exciting novel agents...
  15. ncbi request reprint Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 22:4711-6. 2004
    ..Revised response rates based on International Workshop Response Criteria are also provided...
  16. doi request reprint Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression
    Scott H Olejniczak
    Departments of Immunology and Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 14:1550-60. 2008
    ..In an attempt to define strategies to overcome rituximab resistance, we sought to determine the chemotherapy sensitivity of our rituximab-resistant cell lines (RRCL)...
  17. doi request reprint The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review
    Denise M Oliansky
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Biol Blood Marrow Transplant 17:20-47.e30. 2011
    ..Areas of needed research in the treatment of DLBCL with SCT were identified and are presented in the review...
  18. ncbi request reprint Rituximab in combination with CHOP or fludarabine in low-grade lymphoma
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Semin Oncol 29:36-40. 2002
    ..One approach to the development of innovative strategies for treatment of NHL has been the generation of monoclonal antibodies to specific B-cell antigens expressed on NHL cells...
  19. ncbi request reprint Immunochemotherapy in indolent non-Hodgkin's lymphoma
    Myron S Czuczman
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Semin Oncol 29:11-7. 2002
    ..The combination of rituximab with conventional chemotherapeutic agents such as CHOP appears to be a viable treatment option for indolent NHL. Ongoing and planned studies will lead to the optimal use of rituximab for the treatment of NHL...
  20. ncbi request reprint Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana
    Myron S Czuczman
    Lymphoma Myeloma Service, Lymphoma Translational Research Laboratory, Roswell Park Cancer Institute, Buffalo, New York, USA
    Clin Adv Hematol Oncol 8:A1-11. 2010
    ..The crucial data presented at the 2009 ASH annual meeting are discussed and evaluated by 2 leading experts in the treatment of NHL, Drs. Myron S. Czuczman and Mathias J. Rummel...
  21. ncbi request reprint Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches
    Francisco J Hernandez-Ilizaliturri
    Lymphoma Myeloma Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    Oncology (Williston Park) 23:546-53. 2009
    ..This two-part review summarizes treatment options for patients with relapsed/refractory DLBCL and stresses the emerging therapeutic challenges for patients who were previously exposed to rituximab...
  22. ncbi request reprint Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
    Francisco J Hernandez-Ilizaliturri
    Department of Medicine, Roswell Park Cancer Institute Buffalo, New York 14263, USA
    Clin Cancer Res 11:5984-92. 2005
    ..Augmenting NK cell function by CC-4047 or CC-5013 exposure may increase the antitumor effects of rituximab against B-cell lymphomas and warrants further exploration in the context of a clinical trial...
  23. ncbi request reprint CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymp
    Raymond I Cruz
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 48:2424-36. 2007
    ..Our current data provides a basis for further evaluation of alemtuzumab-based clinical trials for patients with rituximab-resistant NHL...
  24. ncbi request reprint Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model
    Francisco J Hernandez-Ilizaliturri
    Department of Medicine, Roswell Park Cancer Institute Buffalo, New York 14263, USA
    Clin Cancer Res 9:5866-73. 2003
    ..The purpose of this work was to study the effect(s) of neutrophils on the in vivo antitumor activity of rituximab...
  25. ncbi request reprint The role of surgical intervention in non-Hodgkin's lymphoma of the colon and rectum
    Steven Cai
    Department of Surgery, The State University of New York at Buffalo, Buffalo, NY, USA
    Am J Surg 193:409-12; discussion 412. 2007
    ..The purpose of the current study was to determine the incidence, presentation, and management of patients with NHL of the colon or rectum...
  26. ncbi request reprint Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
    Leo I Gordon
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611 2927, USA
    Semin Oncol 29:87-92. 2002
    ..These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise...
  27. ncbi request reprint Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study
    Asher Chanan-Khan
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 24:5343-9. 2006
    ..Given the dramatic activity of lenalidomide in other B-cell malignancies and its pleotropic immunomodulatory effects, we conducted a phase II trial of this agent in CLL...
  28. ncbi request reprint Prevention and management of cardiotoxicity from antineoplastic therapy
    Asher Chanan-Khan
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Support Oncol 2:251-6; discussion 259-61, 264-6. 2004
    ....
  29. ncbi request reprint Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20
    Sreeram Maddipatla
    School of Medicine, State University of New York at Buffalo, Buffalo, New York, USA
    Clin Cancer Res 13:4556-64. 2007
    ..Theoretically, synergistic antitumor activity should be observed by combining TRAIL-R mAbs with agents (e.g., rituximab) that activate the intrinsic apoptotic pathway...
  30. doi request reprint The use of galiximab in non-Hodgkin lymphoma
    Sanjay Vinjamaram
    Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14202, USA
    Clin Lymphoma Myeloma 8:277-82. 2008
    ..Ongoing and future studies are warranted to further evaluate the therapeutic role of galiximab in the treatment of patients with B-cell lymphomas in combination with rituximab or systemic chemotherapy...
  31. doi request reprint Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial
    Asher Chanan-Khan
    Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY 14051, USA
    Leuk Lymphoma 50:1096-101. 2009
    ..1-not reached). Fatigue and sensory neuropathy were the most common side effects noted. We observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma...
  32. ncbi request reprint Bcl-2 antisense therapy in B-cell malignant proliferative disorders
    Asher Chanan-Khan
    Department of Medicine, Lymphoma Myeloma Section, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Curr Treat Options Oncol 5:261-7. 2004
    ..As current data mature, these trials will hopefully validate preliminary results and establish Bcl-2 antisense as an important addition to the current armamentarium used in the treatment of patients with B-cell neoplasms...
  33. pmc Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study
    Brad S Kahl
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Cancer 116:106-14. 2010
    ..Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma...
  34. ncbi request reprint Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
    Asher Chanan-Khan
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14051, USA
    Blood 106:3348-52. 2005
    ..An ongoing phase 2 part of this study will help validate the clinical efficacy of this regimen...
  35. doi request reprint Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia
    Anjana Elefante
    Department of Pharmacy, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Am J Health Syst Pharm 67:713-23. 2010
    ..The pharmacology, efficacy, safety, and dosage and administration of bendamustine and its use in indolent non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are reviewed...
  36. ncbi request reprint Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma
    Asher Chanan-Khan
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 45:1673-5. 2004
    ..At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL...
  37. ncbi request reprint Radioimmunotherapy in non-Hodgkin lymphoma
    Asher Chanan-Khan
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Curr Opin Oncol 14:484-9. 2002
    ..Durable antitumor responses have been achieved, even in heavily pretreated patients. The optimal position that these novel agents should take in the algorithm of lymphoma therapy remains to be defined...
  38. ncbi request reprint Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion
    Theresa Hahn
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Transplantation 78:1515-22. 2004
    ..This report examines the incidence of and risk factors for allogeneic BMT-associated TM in two patient cohorts treated before and after changes in myeloablative conditioning regimen intensity (high vs. standard intensity)...
  39. ncbi request reprint Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma
    Julie A Baker
    Department of Epidemiology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Causes Control 16:301-8. 2005
    ..48--1.17). Other studies have demonstrated that acetaminophen is associated with transient decreases in DNA repair, and lymphocytes may be particularly susceptible to DNA damage, suggesting a mechanism for the elevated NHL risk observed...
  40. doi request reprint Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response
    Asher Chanan-Khan
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    Cancer 117:2127-35. 2011
    ..In patients with chronic lymphocytic leukemia (CLL), treatment with lenalidomide induces a unique, previously uncharacterized, immune response called tumor flare reaction (TFR). The clinical significance of this reaction remains unknown...
  41. ncbi request reprint Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo
    Nishitha Reddy
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 140:36-45. 2008
    ..Our positive preclinical data adds additional support for the evaluation of IMiDs plus rituximab in patients with relapsed/refractory B-cell lymphoma...
  42. doi request reprint Galiximab: a review
    Seema Bhat
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Expert Opin Biol Ther 10:451-8. 2010
    ..CD80 serves as an attractive target in the continued development of mAbs against lymphoma...
  43. ncbi request reprint Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies
    Sapna Khubchandani
    Roswell Park Cancer Institute, Department of Medicine and Immunology, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Curr Opin Investig Drugs 10:579-87. 2009
    ..In particular, patients with diffuse large B-cell lymphoma responded well to dacetuzumab; the drug is being pursued for this indication in phase II trials...
  44. ncbi request reprint Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab
    Jeyanthi Ramanarayanan
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 127:519-30. 2004
    ..Our findings suggest that Bcl-2 downregulation by G3139, followed by the administration of rituximab is an efficient anti-tumour strategy associated with improved survival in lymphoma-bearing SCID mice...
  45. ncbi request reprint Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics
    Aasma Shaukat
    Department of Medicine, School of Medicine and Biochemical Sciences, SUNY at Buffalo, Buffalo 14263, NY, USA
    Mycopathologia 159:181-8. 2005
    ..The predominance of coagulative necrosis in our series may reflect the high doses of corticosteroids used to treat graft-versus-host disease (GVHD), which may have disabled leukocyte trafficking and hyphal killing...
  46. ncbi request reprint A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry
    Scott H Olejniczak
    Department of Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
    Immunol Invest 35:93-114. 2006
    ..However, a high expression of specific antigens on a given B-cell malignancy may potentially identify optimal therapeutic targets for current and/or future monoclonal antibody-based therapies...
  47. ncbi request reprint Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion
    Myron S Czuczman
    Lymphoma Myeloma Service and Lymphoma Translational Research Laboratory, Roswell Park Cancer Institute, Buffalo, New York, USA
    Clin Adv Hematol Oncol 8:A1-14; quiz A15. 2010
    ..Some of the drug classes examined here are proteasome inhibitors, inhibitors of the protein mammalian target of rapamycin (mTOR), the unique alkylating agent bendamustine, and immunomodulatory agents...
  48. doi request reprint Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
    Taimur Sher
    Department of Medicine, Roswell Park Cancer Institute, NY 14263, USA
    Leuk Lymphoma 51:85-8. 2010
    ..In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics...
  49. doi request reprint Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms
    Wasif Riaz
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Immunol Res 46:192-205. 2010
    ..In this review article, we will provide an overview of various rituximab-associated cytotoxic mechanisms and novel strategies to improve mAb activity against B-cell lymphoma...
  50. ncbi request reprint Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model
    Francisco J Hernandez-Ilizaliturri
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    Leuk Lymphoma 46:1775-84. 2005
    ..3%) compared to rituximab alone (13.3%) or in combination with peg-GM-CSF (26.7%). Increasing neutrophil counts via cytokine stimulation may play an important role in augmenting rituximab-associated antitumor activity...
  51. ncbi request reprint Extra copies of chromosome 2 are a recurring aberration in ALK-negative lymphomas with anaplastic morphology
    Rina Kansal
    Department of Pathology, Buffalo General Hospital, The State University of New York, Buffalo, NY, USA
    Mod Pathol 18:235-43. 2005
    ..Further investigation of this finding is necessary to further our understanding of the heterogeneous group of ALK- lymphomas...
  52. ncbi request reprint The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma
    Theresa Hahn
    Roswell Park Cancer Institute, Buffalo, NY, USA
    Biol Blood Marrow Transplant 9:667. 2003
  53. ncbi request reprint Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies
    Francisco J Hernandez-Ilizaliturri
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Oncology (Williston Park) 23:610-5. 2009
    ....
  54. doi request reprint Sixth International Workshop on non-Hodgkin Lymphoma: 16-17 November 2007, Boston, USA
    Myron S Czuczman
    Lymphoma and Myeloma Service and Lymphoma Translational Research Laboratory, Roswell Park Cancer Institute, Buffalo, New York, USA
    Leuk Lymphoma 49:4-6. 2008
    ..Czuczman, Head, Lymphoma and Myeloma Service and Lymphoma Translational Research Laboratory at Roswell Park Cancer Institute, Buffalo, NY, on behalf of the Scientific Advisory Committee, to corporate sponsors, speakers and attendees...
  55. ncbi request reprint Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature
    Stephen M Ansell
    Division of Hematology Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Clin Lymphoma 5:202-4. 2004
    ....
  56. ncbi request reprint Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
    Thomas E Witzig
    Mayo Clinic, 620 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:3262-9. 2002
    ..Ibritumomab tiuxetan radioimmunotherapy targets the same antigen as rituximab and has demonstrated efficacy in rituximab-naïve NHL. This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refractory follicular NHL...
  57. ncbi request reprint Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, 60 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:2453-63. 2002
    ....
  58. ncbi request reprint Rituximab therapy for indolent non-Hodgkin's lymphoma
    Anton Hagenbeek
    University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands
    Anticancer Drugs 13:S11-7. 2002
    ..Rituximab is therefore an excellent treatment option both as first-line and as salvage therapy for patients with indolent NHL...
  59. ncbi request reprint Non-Hodgkin's lymphomas
    Andrew D Zelenetz
    J Natl Compr Canc Netw 6:356-421. 2008
  60. ncbi request reprint Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma
    Kevin R Imrie
    Toronto Sunnybrook Regional Cancer Center, Toronto, Canada
    Anticancer Drugs 13:S19-24. 2002
    ....
  61. ncbi request reprint Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Robert M Sharkey
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA
    J Nucl Med 44:2000-18. 2003
    ..Of particular interest was to evaluate whether pretherapy targeting and tumor dosimetry could predict therapeutic responses...
  62. ncbi request reprint Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology
    Andrew D Zelenetz
    J Natl Compr Canc Netw 4:258-310. 2006
  63. ncbi request reprint Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies
    David J Straus
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:1909-17. 2006
    ..Chemotherapy-related anemia is prevalent among patients with hematologic malignancies. A randomized, open-label, multicenter trial of early versus late epoetin alfa in this population was conducted, focusing on quality of life (QOL)...
  64. pmc Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network
    Ann S LaCasce
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5107-12. 2008
    ..We sought to estimate the impact of expert review in the modern era by comparing final pathologic diagnoses at five comprehensive cancer centers with diagnoses assigned at referring centers...
  65. ncbi request reprint NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer
    Donald A Podoloff
    J Natl Compr Canc Netw 5:S1-22; quiz S23-2. 2007
    ..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...
  66. ncbi request reprint Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAART
    Sridhar Srinivasan
    Department of Medicine, State University of Buffalo, New York
    HIV Clin Trials 5:140-5. 2004
    ..We studied whether the introduction of HAART is associated with improved survival in patients with GI-ARL...

Research Grants2